BRUKINSA demonstrated a 74% 6-year progression-free survival rate in treatment-naïve CLL patients, reinforcing its efficacy as a foundational therapy.
These long-term efficacy data for BRUKINSA in treatment-naïve CLL patients are highly significant, establishing it as a durable and effective foundational therapy. This reinforces its value proposition for healthcare providers and patients globally. In APAC, where CLL incidence is notable, these results will influence treatment guidelines and patient selection, potentially leading to wider adoption and improved outcomes.
BRUKINSA achieved 74% 6-year PFS in treatment-naïve CLL.
Demonstrates long-term efficacy and durability.
Reinforces foundational treatment status for CLL.
The strong long-term efficacy of BRUKINSA in treatment-naïve CLL is crucial for APAC markets. CLL is a significant hematological malignancy in the region. These data will support market access, reimbursement discussions, and physician confidence, potentially leading to increased use of BRUKINSA as a first-line treatment for CLL patients across Asia-Pacific.
Reinforces foundational treatment status for CLL.
Data presented at ASH 2025.
登录后可保存信号笔记。
登录